US Congress HR6625

Link to Summary Link to Summary

Link to Full Text Link to Full Text

On February 8, 2022 in the House:

Referred to the Subcommittee on Health.

On February 7, 2022 in the House:

Introduced in House
Referred to the House Committee on Energy and Commerce.

US - Representative Rodney Davis (R)

Type:

Primary Sponsor

US - Representative Andrew R. Garbarino (R)

US - Representative Beth Van Duyne (R)

US - Representative Bob Gibbs (R)

US - Representative Chris Jacobs (R)

US - Representative Claudia Tenney (R)

US - Representative David B. McKinley (R)

US - Representative Doug Lamborn (R)

US - Representative Glenn Grothman (R)

US - Representative Jason Smith (R)

US - Representative Jefferson Van Drew (R)

US - Representative Jeff Fortenberry (R)

US - Representative Kat Cammack (R)

US - Representative Mike Bost (R)

US - Representative Nicole Malliotakis (R)

US - Representative Randy Feenstra (R)

US - Representative Sam Graves (R)

US - House Energy and Commerce (House)

Show previous .

Participants:

{{ teamMember.name ? teamMember.name : teamMember.email | escapeHtml | nl2br | trustHTML }} {{ teamMember.name ? teamMember.name : teamMember.email | escapeHtml | nl2br | trustHTML }}

{{ teamMember.name ? teamMember.name : teamMember.email | escapeHtml | nl2br | trustHTML }}

{{discussion.createdAt}} | delete | deleting | edit | cancel

Nothing posted by your team.

Select categories:

Clear all

+ New Note

US Congress HR6625

To prohibit the Secretary of Health and Human Services from issuing guidance intended to restrict access to COVID-19 monoclonal antibody therapies and other treatments.

+ − Bill Search

Table of Contents

Tools

+ − Summary

+ − Full Texts (2)

+ − Actions (3)

+ − Sponsors (17)